Drug Non-Adherence Costs Manufacturers Billions Of Dollars In Revenues – Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Capgemini’s calculations of potential pharmaceutical revenues if patients were fully compliant with their drug therapy regimens suggest revenues in the U.S. would be nearly 60% higher. But even small changes have sizeable revenue impact.